<DOC>
	<DOCNO>NCT01269528</DOCNO>
	<brief_summary>Protocol Synopsis : There link early RSV infection chronic respiratory morbidity . Hypothesis : Palivizumab administration may result decreased AHR low respiratory morbidity . Primary objective : evaluate prospectively effect palivizumab airway reactivity ( AHR ) child bear 29-32 week . Secondary objective : ass prospectively effect palivizumab respiratory morbidity airway inflammation allergy child bear 29-32 week . Inclusion criterion : premature baby 29-32 week gestation born 2007 2010 . Exclusion criterion : Any mechanical ventilation chronic disease , e.g. , bronchopulmonary dysplasia ( BPD ) , cystic fibrosis ( CF ) , congenital heart disease , congenital anomaly , know immunodeficiency , receipt RSV investigative vaccine therapy . Primary end point : Airway reactivity assess methacholine challenge test determination PC20 . Secondary end point : Respiratory morbidity assess questionnaire telephone interview . Additionally , IGE , eosinophil count , exhale NO evaluate . Sample size : 74 participant ; Group I - 37 premature baby 29-32 week gestation bear 2007-2008 ( approval Synagis group Israel ) . Group II - 37 premature baby 29-32 week gestation bear 2009-2010 ( approval Synagis group Israel ) . Statistics : A sample size 37 patient calculate necessary detect difference 0.5 SD AHR 2-sided tail , power 80 % . Demographics baseline characteristic compare use 1-way analysis variance quantitative variables Fisher 's exact test categorical variable .</brief_summary>
	<brief_title>Prospective Evaluation Efficacy Palivizumab Administration Children Born 29-32 Weeks Gestation</brief_title>
	<detailed_description>Protocol Synopsis : There link early RSV infection chronic respiratory morbidity . Hypothesis : Palivizumab administration may result decreased AHR low respiratory morbidity . Primary objective : evaluate prospectively effect palivizumab airway reactivity ( AHR ) child bear 29-32 week . Secondary objective : ass prospectively effect palivizumab respiratory morbidity airway inflammation allergy child bear 29-32 week . Inclusion criterion : premature baby 29-32 week gestation born 2007 2010 . Exclusion criterion : Any mechanical ventilation chronic disease , e.g. , bronchopulmonary dysplasia ( BPD ) , cystic fibrosis ( CF ) , congenital heart disease , congenital anomaly , know immunodeficiency , receipt RSV investigative vaccine therapy . Primary end point : Airway reactivity assess methacholine challenge test determination PC20 . Secondary end point : Respiratory morbidity assess questionnaire telephone interview . Additionally , IGE , eosinophil count , exhale NO evaluate . Sample size : 74 participant ; Group I - 37 premature baby 29-32 week gestation bear 2007-2008 ( approval Synagis group Israel ) . Group II - 37 premature baby 29-32 week gestation bear 2009-2010 ( approval Synagis group Israel ) . Statistics : A sample size 37 patient calculate necessary detect difference 0.5 SD AHR 2-sided tail , power 80 % . Demographics baseline characteristic compare use 1-way analysis variance quantitative variables Fisher 's exact test categorical variables..</detailed_description>
	<mesh_term>Bronchial Hyperreactivity</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Methacholine Chloride</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Premature baby 2932 week gestation born 2007 2010 Any mechanical ventilation Chronic disease , e.g. , bronchopulmonary dysplasia ( BPD ) , cystic fibrosis ( CF ) , congenital heart disease , congenital anomaly Known immunodeficiency Receipt RSV investigative vaccine therapy</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Palivizumab</keyword>
	<keyword>Airway Hyperreactivity</keyword>
	<keyword>EBC</keyword>
	<keyword>MCT</keyword>
</DOC>